Acute myeloid leukemia (AML) is a malignant condition of poorly differentiated hematopoietic progenitor cells.1 The disease can manifest in the eye with tissue hemorrhage or infiltration and be the presenting sign of systemic disease or evidence of relapse. Most frequently, leukemic infiltration involves the retina or choroid, whereas iridociliary involvement is rare.2,3 Management of the systemic disease is key to controlling leukemic ophthalmopathy, but often the eye requires additional radiotherapy, especially for optic-nerve involvement.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kim RS, Yaghy A, Wilde LR, Shields CL. An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor. JAMA Ophthalmol. 2020;138(4):418–419. doi:10.1001/jamaophthalmol.2020.0110
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: